Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin

被引：29
作者：
Arhin, Francis F. [1 ]
Sarmiento, Ingrid [1 ]
Parr, Thomas R., Jr. [1 ]
Moeck, Gregory [1 ]
机构：
[1] Med Co, St Laurent, PQ, Canada
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2009年 / 64卷 / 04期
关键词：
glycopeptide non-susceptible; MICs; MBCs;
D O I：
10.1093/jac/dkp286
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：868 / 870
页数：3
相关论文
共 6 条
  • [1] [Anonymous], M100S18 CLSI S
  • [2] Heteroresistance: a concern of increasing clinical significance?
    Falagas, M. E.
    Makris, G. C.
    Dimopoulos, G.
    Matthaiou, D. K.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 (02) : 101 - 104
  • [3] FRITSCHE TR, 2008, 48 INT C ANT AG CHEM, P96
  • [4] Key considerations in the treatment of complicated staphylococcal infections
    Jones, R. N.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 : 3 - 9
  • [5] Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium
    McKay, Geoffrey A.
    Beaulieu, Sylvain
    Arhin, Francis F.
    Belley, Adam
    Sarmiento, Ingrid
    Parr, Thomas, Jr.
    Moeck, Gregory
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (06) : 1191 - 1199
  • [6] *NAT COMM LAB STAN, 1999, M26A NCCLS
1